-
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease
16 Jun 2025 06:13 GMT
(MENAFN- GlobeNewsWire - Nasdaq) Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease Prasinezumab is a potential first-in-class anti-alpha-synuclein …
-
Smartphone App Can Track Huntington's Disease Symptoms
12 Jun 2025 11:56 GMT
Key Takeaways
A new app can help track progression of Huntington’s disease
The app uses five tests of movement control to provide insight into motor control
This measure was twice as accurate as the current standard measure
THURSDAY, June 12, 2025 ( …
-
Smartphone tests could enhance the detection of Huntington's disease progression
10 Jun 2025 02:48 GMT
A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) …
-
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight
03 Jun 2025 17:00 GMT
New York, USA, June 03, 2025 (GLOBE NEWSWIRE) -- Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight The Huntington's disease treatment market is …
-
pRxEngage Launches to Revolutionize Clinical Trial Access and Engagement
20 May 2025 08:00 GMT
New Platform Aims to Remove Barriers and Restore Trust in Clinical Trials Through Simplicity and Transparency
LONDON, UNITED KINGDOM, May 20, 2025 /EINPresswire.com/ -- pRxEngage, a groundbreaking platform designed to transform how clinical …
-
SMALL CAP IDEA: Ixico embraces artificial intelligence for new Alzheimer's treatments
19 May 2025 15:05 GMT
Alzheimer's disease costs the global economy $1.3trillion a year. That is the estimate from the Alzheimer's Society, reflecting the growing burden of care, treatment and lost productivity as populations age.
Add in other neurodegenerative diseases …
-
Huntington's Disease Treatment Market To Hit $2.03 Billion By 2033, Driven By Cutting-Edge Therapies
18 Apr 2025 10:10 GMT
(MENAFN- GlobeNewsWire - Nasdaq) Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbeck and Pfizer are fueling research and development efforts worldwide.
…
-
At the Bedside: Parents of Daughters with Rare Juvenile-Onset Huntington's Disease Find UTHealth Houston Center of Excellence for Care and Support
15 May 2025 03:14 GMT
Newswise — In 2020, when she was 4 years old, Khloe Gloria stopped walking.
At the suggestion of their local San Angelo physician, her concerned parents took her to see neurologists in Dallas. Khloe’s mom, Natalie Salazar, already had a sinking feeling she …
-
Global Huntington's Disease Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
13 May 2025 05:42 GMT
The Business Research Company’s Huntington's Disease Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, May 13, 2025 /EINPresswire.com/ -- The market for Huntington's disease …
-
Mitochondrial DNA editing offers new hope for neurodegenerative disease treatment
13 May 2025 01:33 GMT
Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs). As these diseases continue to impose a significant global health burden, the innovative use of mitochondrial gene editing …
About
© 1995-2025